💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Wanbury Limited is an India-based pharmaceutical company with a presence in the active pharmaceutical ingredients (APIs) global market and domestic branded formulations. The Company is engaged in the business of pharmaceutical and related activities, including research. Its…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, stagnant business, fairly priced — carrying meaningful debt.
WANBURY LIMITED is scored on the pharma / healthcare framework. It keeps a slim 5.1% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.85×). Free cash flow is worth about -3.6% of its market value.
Over the last 3 years revenue compounded at 6%/yr and profit at -28%/yr. Return on equity is an elite 51.5%. In the latest quarter profit fell 33% versus the prior quarter.
At 21× earnings, the stock sits at the 59th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price implies ~6%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 15.67 | — | — |
| P/B | 8.69 | 4.11 | worse |
| EV/EBITDA | 9.02 | 19.15 | better |
| ROE | 51.51 | — | — |
| ROCE | 27.98 | 6.87 | better |
| ROA | 10.39 | — | — |
| Quick Ratio | 0.89 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
6% CAGR — growing but slowly. Growth is decelerating — latest year grew slower than the year before.
1 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a -45% swing — check if it's a one-off or structural.
Operating margin has compressed from 16% to 5% — costs or competition are eating into profitability.
ROE at 52% — the business earns well above its cost of equity. High ROE despite single-digit margins — an asset-turn play with high capital velocity. Capital efficiency declining — ROE down 149pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. -39% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 6% QoQ — could be seasonality or a genuine slowdown. Run-rate stepping up — recent quarters average 14% above earlier ones.
Profit fell 33% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly net margins are expanding (5% → 8%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 43.0% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.